Free Trial
→ Why buying gold might be a mistake (From DTI) (Ad) Free GSK Stock Alerts

GSK (GSK) Stock Forecast & Price Target

GSK logo
GBX 1,301 -52.50 (-3.88%)
(As of 11/15/2024 ET)
Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings
Sell
1
Hold
1
Buy
5

Based on 7 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 1 has given a hold rating, and 5 have given a buy rating for GSK.

Consensus Price Target

GBX 1,842.50
According to the 7 analysts' twelve-month price targets for GSK, the average price target is GBX 1,842.50. The highest price target for GSK is GBX 2,100, while the lowest price target for GSK is GBX 1,660. The average price target represents a forecasted upside of 41.62% from the current price of GBX 1,301.
Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

Sign Up

GSK Analyst Ratings Over Time

TypeCurrent Forecast
11/18/23 to 11/17/24		1 Month Ago
10/19/23 to 10/18/24		3 Months Ago
8/20/23 to 8/19/24		1 Year Ago
11/18/22 to 11/18/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 1,842.50GBX 1,842.50GBX 1,805.71GBX 1,573.64
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical Companies
Consensus Rating Score
2.57
2.80
Consensus RatingModerate BuyModerate Buy
News Sentiment Rating
Neutral News

See Recent GSK News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/10/2024Berenberg Bank
2 of 5 stars		 Reiterated RatingBuyGBX 1,820+9.90%
9/3/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars		 Reiterated RatingBuyGBX 1,850+11.78%
8/28/2024Shore Capital
1 of 5 stars		 Reiterated RatingBuy
7/29/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingUnderweight
7/5/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuyGBX 2,120 ➝ GBX 1,900+24.79%
6/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuyGBX 2,100+38.25%
5/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingEqual WeightGBX 1,725-1.96%
9/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetGBX 1,440 ➝ GBX 1,585+3.39%
7/17/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetGBX 1,450 ➝ GBX 1,390+5.22%
3/6/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Keyur Parekh
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetGBX 2,000+38.68%
2/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Dominic Lunn
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingNeutralGBX 1,510+6.16%
2/1/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Michael Leuchten
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetGBX 1,245-13.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:47 AM ET.


Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 28, 2024. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in GSK plc:

  • GSK plc has a diverse portfolio of vaccines and specialty medicines, including products for HIV, oncology, respiratory/immunology, and other specialty medicine products.
  • The company is actively engaged in research and development, with collaborations in place for the development of mRNA-based influenza vaccines and oligonucleotide platform development.
  • GSK plc recently announced a dividend, providing investors with a return on their investment.
  • Wall Street analysts have forecasted growth for GSK plc, with several brokerages giving buy ratings and positive price targets.
  • Despite market fluctuations, GSK plc has maintained a stable financial position with a reasonable debt-to-equity ratio, ensuring financial stability.

GSK
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in GSK plc for these reasons:

  • GSK plc's stock price has shown volatility in the past, with fluctuations in the market impacting the share value.
  • The company operates in a highly competitive industry, facing challenges from other pharmaceutical companies and potential regulatory hurdles.
  • While GSK plc has a diverse product portfolio, market demand and competition could impact the sales and profitability of its offerings.
  • Investors need to consider the potential impact of global health crises or regulatory changes on GSK plc's operations and financial performance.
  • Market conditions and economic factors can influence the overall performance of GSK plc, requiring investors to monitor external factors closely.

GSK Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 1,842.50, with a high forecast of GBX 2,100 and a low forecast of GBX 1,660.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There is currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GSK shares.

According to analysts, GSK's stock has a predicted upside of 41.62% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, and Shore Capital in the past 90 days.

Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.57 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GSK compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (LON:GSK) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners
There is a little known company that is changing warfare
With geo - political instability around the world investors are flocking to defense contract stocks. There...
Reticulate | Sponsored